Immune fitness and response to taclistamab in R/R multiple myeloma; BCR::ABL1 M244V mutation causes resistance to asciminib; HSCT and myocardial fibrosis in young patients with SCD

In this week's episode we’ll discuss how immune fitness impacts response to teclistamab in relapsed/refractory multiple myeloma; learn more about a new mechanism of resistance to asciminib conferred by the BCR::ABL1 M244V mutation, and discuss the impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease.

Featured Articles:

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib
Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease

Om avsnittet

Fler avsnitt

Designing Durable Remissions in Relapsed AML and Follicular Lymphoma

Dose Makes the Cure: Venetoclax in Ph- ALL

Exploiting Vulnerabilities in High‑Risk MM and Mapping the Red Cell Interactome

MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow

Predictive Markers of Glofitamab Resistance in R/R B-NHL

Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM

Balancing Infection and Thrombosis: Bispecific Antibodies and the Many Roles of HRG

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

FLT3-ITD microclones in AML and Results from the RESET-PV trial